The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience
Abstract
Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from HPS occur within 48 h of hospitalization. Thirty patients with confirmed HPS, 105 patients without HPS and 5 patients without adequate diagnostic testing for HPS were enrolled. This observational study arguably provides the most complete information available on ribavirin-associated adverse effects. Although ribavirin was generally well tolerated, 71% of recipients became anaemic and 19% underwent transfusion. An apparent excess of hyperamylasaemia/pancreatitis was either therapy-associated or due to enrolment bias. The 30 enrolled HPS patients had a case–fatality rate of 47% (14/30). It is not possible to assess efficacy with this study design. However, comparison of survival curves for the 30 enrolled HPS patients and 34 patients who developed HPS during the same time period but were not enrolled did not suggest an appreciable drug effect. A randomized, placebo-controlled trial that enrols patients during the prodrome phase would be necessary to assess the efficacy and further define the safety of intravenous ribavirin for HPS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Mitochondrial toxicity–new adverse drug effects
Swartz, M. N. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331710 · Cited by 80 · cited 1×
“Nucleoside analogues have been associated with the induction of pancreatitis [27–29].”
Background
Cited by
A Global Perspective on Hantavirus Ecology, Epidemiology, and Disease
Jonsson, C. B., Figueiredo, L. T. M., & Vapalahti, O. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00062-09 · Cited by 1,134
Mandell, L. A., Bartlett, J. G., Dowell, S. F., File, T. M., Musher, D. M., & Whitney, C. (2003) · Clinical Infectious Diseases · doi:10.1086/380488 · Cited by 1,004
Avšič-Županc, T., Saksida, A., & Korva, M. (2019) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12291 · Cited by 380
MacNeil, A., Nichol, S. T., & Spiropoulou, C. F. (2011) · Virus Research · doi:10.1016/j.virusres.2011.09.017 · Cited by 275
Hemorrhagic Fever with Renal Syndrome: Pathogenesis and Clinical Picture
Jiang, H., Du, H., Wang, L. M., Wang, P. Z., & Bai, X. F. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00001 · Cited by 274
Metadata
- Authors
- Chapman, L. E., Mertz, G. J., Peters, C. J., Jolson, H. M., Khan, A. S., Ksiazek, T. G., Koster, F. T., Baum, K. F., Rollin, P. E., Pavia, A. T., Holman, R. C., Christenson, J. C., Rubin, P. J., Behrman, R. E., Bell, L. J. W., Simpson, G. L., Sadek, R. F., The Ribavirin Study Group, Armstrong, B., Atterbury, B., Baacke, G., Bellardi, D., Carroll, M., Cheek, J., Craig, A., Daniels, D., Freeman, W., Held, F., Kessler, D., Konicck, S., Light, A., McGee, J., Savage, J., Sloan, M., Tempest, B., Vaughan, K., Waite, D., Becher, J., Brieman, R., Bulter, J., Schmidt-Dalton, M., Hart, D., Hawk, J., Khabbaz, R., Lloyd, E., Sortir, M., Stokes, S., Torok, T., Vitek, C., Harding;, S., England, R., Kioski, C., Mosley, D., Sands, L., Johnson-Baach, T., Ronnau, K., Mast, D., Servi, R., Levinson, R., Yeager, F., Adam, R., Friedman, B., Lincoln, L., Petersen, E., Wack, E., Moncada, R., Bassi, S. S., Rumack, J., Kuriyama, S., McGovern, J., Olson, D., Garst, P., Butera, M., Erlich, K., Dinolfo, M., Dalton, C., Hoffman, R., Kuritzkes, D., Madinger, N., Schooley, R., Mass, A., Hofflin, J., Britton, K., Blum, R., Cott, G., Golub, B., Greenberg, K., Lichtenstien, K., O'Brien, R., Motley, R., Culliman, M., Fujeta, N., Mason, S., McLeod, G., Mateos-Mora, M., Demers, D., Jackson, C., Zar, B., Ramakrishna, B., Jones, C., Lucht, W., Conrad, S., Grier, L., King, J., Adelso, J., Kim-Karpe, M., Bergman, M., Schut, R., Sterling, T., Brewer, J., Anderson, D., Roehrs, J., Dietrich, J., Jones, D., Ward, C., Stockfish, J., Allen, S., Crowell, R., Cushing, A., Goade, D., Irizarry, L., Jenison, S., Levy, H., Overturf, G., Palmer, D., Quenzer, R., Reed, W., Simpson, S., Williams, J., Berger, B., Hussain, F., Berger, B., Sepe, F., Hargreaves, J., Baddour, L., Parrish, R., Plemmons, R., Radolf, J., Szeyko, G., Elkind, K., Knight, V, Badger, M., Furlan, J., Gillum, M., Tice, A., & Barany, J.
- Venue
- Antiviral Therapy
- Publisher
- SAGE Publications
- Published
- 1999-05
- Volume
- 4
- Issue
- 4
- Pages
- 211-219
- ISSN
- 1359-6535 (ISSN-L)
- 2040-2058
- OpenAlex
- W192855520
- Cited by
- 170
- References
- 2
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience. https://app.cochat.ai/papers/10.1177/135965359900400404
- The paper
- Chapman, L. E., Mertz, G. J., Peters, C. J., Jolson, H. M., Khan, A. S., Ksiazek, T. G., Koster, F. T., Baum, K. F., Rollin, P. E., Pavia, A. T., Holman, R. C., Christenson, J. C., Rubin, P. J., Behrman, R. E., Bell, L. J. W., Simpson, G. L., Sadek, R. F., The Ribavirin Study Group, Armstrong, B., . . . Barany, J. (1999). Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience. Antiviral Therapy. https://doi.org/10.1177/135965359900400404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.